Pfizer (PFE) R&D president earns 13,383 shares, withholds 6,833 for taxes

Rhea-AI Filing Summary

Pfizer Inc. President of R&D Christoffel Boshoff reported equity award activity involving Pfizer common stock. On February 25, 2026, he acquired 13,383 shares at $0.0000 per share as the earn-out of performance share awards, including dividend equivalents, increasing his direct holdings to 168,212 shares.

On the same date, 6,833 shares were disposed of at $27.09 per share to cover tax obligations related to this earn-out, a tax-withholding disposition rather than an open-market sale, leaving 161,379 shares held directly. He also indirectly holds 709 shares through a Rule 16b-3 plan.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider BOSHOFF CHRISTOFFEL

Role President, R&D

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	13,383	$0.00	--
Tax Withholding	Common Stock	6,833	$27.09	$185K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 168,212 shares (Direct); Common Stock — 709 shares (Indirect, By Rule 16b-3 Plan)

Footnotes (1)

1. The reported transaction constitutes the earn-out of performance share awards (including dividend equivalents thereon). The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of performance share awards (including dividend equivalents thereon).

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOSHOFF CHRISTOFFEL

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		A		13,383(1)	A	$0.0000	168,212	D
Common Stock	02/25/2026		F		6,833(2)	D	$27.09	161,379	D
Common Stock								709	I	By Rule 16b-3 Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction constitutes the earn-out of performance share awards (including dividend equivalents thereon).

2. The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of performance share awards (including dividend equivalents thereon).

	/s/ Shanice A. Reid, by power of atty, for Christoffel Boshoff	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Pfizer (PFE) executive Christoffel Boshoff report?

Christoffel Boshoff reported an earn-out of performance share awards and related tax withholding. He acquired 13,383 Pfizer common shares and had 6,833 shares withheld to satisfy tax obligations tied to that award.

How many Pfizer (PFE) shares did Christoffel Boshoff acquire in the latest Form 4?

Boshoff acquired 13,383 Pfizer common shares as an earn-out of performance share awards, including dividend equivalents. This non-cash grant increased his direct holdings before tax withholding to 168,212 shares of Pfizer common stock.

Why were some Pfizer (PFE) shares disposed of in Christoffel Boshoff’s Form 4?

The 6,833 shares reported as disposed were withheld to satisfy tax obligations from the performance share award earn-out. This is a tax-withholding disposition under code F, not an open-market sale of Pfizer shares.

What is Christoffel Boshoff’s Pfizer (PFE) share ownership after these transactions?

After the award and tax withholding, Boshoff directly holds 161,379 Pfizer common shares. He also has 709 additional shares held indirectly through a Rule 16b-3 plan, as disclosed in the Form 4 filing.

What do the footnotes in Christoffel Boshoff’s Pfizer (PFE) Form 4 explain?

The footnotes clarify that the acquisition reflects an earn-out of performance share awards with dividend equivalents, and the disposition reflects shares withheld to cover taxes on that earn-out, rather than discretionary buying or selling in the market.